Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc
Bullboard Posts
User Avatar Image
(17)
•••
Post by cpacon Oct 31, 2019 9:05am
424 Views
Post# 30290971

This is SIGNIFICANT NEWS for a number of reasons:

This is SIGNIFICANT NEWS for a number of reasons:Really happy with this news!

1.  ONC's partners have access to the SOLTI data in real time, the timing of this news suggests Adlai was happy with  what they saw.

2.  This will trigger milestone payments for ONC soon from Adlai to the tune of about $8MM USD by the time they enroll 50th patient

3.  Confirmation that we will now have two phase III  trials ongoing globally

4.  I think people had forgotten about this partnership or thought it wasn't progressing because we hadn't heard anything recently.

5.  The trial results will be better than anything ONC  has done before because we now have the biomarker data to guide who will respond to treatment.

6.  Perhaps most importantly, this will light a fire under our big pharma partners who are sure to take notice of this development...

CPAC
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities